NCT03088059 2023-11-03
UPSTREAM
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2 Unknown
Clinical Trials
11 trialsNCT05267288 2023-03-29
Phase II Study of Afatinib Plus Bevacizumab in the Treatment Epidermal Growth Factor Receptor (EGFR) Exon G719X, S768I, and L861Q Mutation Metastatic Non-Small Cell Lung Cancer
Qingdao Central Hospital
Phase 2 Unknown
NCT03574402 2022-12-06
TRUMP
Guangdong Association of Clinical Trials
Phase 2 Unknown
NCT03239015 2022-03-04
Efficacy and Safety of Precision Therapy in Refractory Tumor
Shanghai Changzheng Hospital
Phase 2 Unknown
NCT04880811 2021-07-13
Afatinib Plus Toripalimab in Previously Treated ESCC With EGFR Overexpression or EGFR Amplification
Peking University
Phase 2 Unknown
NCT04533321 2020-08-31
A Biomarker-implemented Clinical Study Evaluating Mutations in MET and TP53 in a Population of Treatment-refractory Squamous Cell Carcinoma
National University Hospital, Singapore
Phase 2 Unknown
NCT01746251 2020-07-07
Adjuvant Afatinib in Stage I-III NSCLC With EGFR Mutation
Massachusetts General Hospital
Phase 2 Unknown
NCT02353936 2019-02-11
A Phase II Trial of Afatinib in Patients With Metastatic or Recurrent Squamous Cell Carcinoma of Esophagus
Yonsei University
Phase 2 Unknown
NCT03810872 2019-01-22
An Explorative Study of Afatinib in the Treatment of Advanced Cancer Carrying an EGFR, a HER2 or a HER3 Mutation
AZ-VUB
Phase 2 Unknown
NCT01728818 2017-07-19
ACCEPT
Ludwig-Maximilians - University of Munich
Phase 2 Unknown
NCT02511847 2016-04-15
Trial of Afatinib With Paclitaxel for Neoadjuvant Therapy of TNBC and Research of Biomarkers of Afatinib
National Taiwan University Hospital
Phase 2 Unknown